Informações:
Sinopse
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.
Episódios
-
Episode 168: The GIPS-IV Study
08/02/2023 Duração: 08minMarie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.
-
Episode 167: The Spyral HTN-ON MED Pilot Study
01/02/2023 Duração: 05minFelix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.
-
Episode 166: Chronic Kidney Disease In CANTOS
11/01/2023 Duração: 07minPaul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.
-
Episode 165: The STAR-T/D Trial
04/01/2023 Duração: 04minMichael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.
-
Episode 164: The LOOP Study for AF Screening
14/12/2022 Duração: 16minC. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.
-
Episode 163: The ENVISAGE-TAVI AF Trial
07/12/2022 Duração: 07minC. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.
-
Episode 162: The FIGARO-DKD Trial
23/11/2022 Duração: 07minEpisode 162: The FIGARO-DKD Trial by TCTMD
-
Episode 161: AMULET-IDE: One-Year Outcomes
09/11/2022 Duração: 06minC. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.
-
Episode 160: Shock Classification Gets an Update
02/11/2022 Duração: 04minC. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.
-
Episode 159: MICHELLE: Rivaroxaban in COVID-19
19/10/2022 Duração: 07minC. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.
-
Episode 158: The RIPCORD 2 Trial
05/10/2022 Duração: 10minC. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.
-
Episode 157: PARTNER 3: Two-Year Economic Outcomes
14/09/2022 Duração: 04minC. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.
-
Episode 156: The IAMI Trial
07/09/2022 Duração: 08minC. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.
-
Episode 155: Two DCBs Go Head to Head in De Novo CAD
25/08/2022 Duração: 12minC. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.
-
Episode 154: The EMPEROR-Preserved Trial
10/08/2022 Duração: 05minC. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.
-
Episode 153: iFR-SWEDEHEART at 5 Years
03/08/2022 Duração: 06minC. Michael Gibson and Matthias Götberg review 5-year findings after iFR- versus FFR-guided PCI.
-
Episode 152: PRONOUNCE: Prostate Cancer Drugs and CVD
20/07/2022 Duração: 10minRenato Lopes and C. Michael Gibson discuss PRONOUNCE comparing the cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and CVD.
-
Episode 151: Stopping Amputation Post-revascularization: Novel Data in Mitigation of Thrombosis Risk
06/07/2022 Duração: 09minDesai and Anahita Dua discuss highlights from a CME program on reducing thrombosis risks in patients with PAD post-revascularization. Claim credit: https://bit.ly/3QTpBt6. Supported by an educational grant from Janssen Scientific Affairs, LLC.
-
Episode 150: The TOMAHAWK Trial
06/07/2022 Duração: 04minC. Michael Gibson and Steffen Desch discuss whether immediate angiography is warranted after out-of-hospital cardiac arrest.
-
Episode 149: The OPTIMUM Trial
22/06/2022 Duração: 05minC. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.